Adjuvant treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitor in renal cell carcinoma after nephrectomy has been reported through three clinical trials:
INTRODUCTION
Renal cell carcinoma cancer (RCC) cases are reported more than 300 000 per year worldwide. 1 Partial or radical nephrectomy followed by observation is the standard of care for RCC tumors. 2 However, up to 40% of patients with locally RCC have a relapse following nephrectomy. 3, 4 The prognosis for patients with RCC is dependent on the stage of disease and other risk factors. The relapse risk can be assessed with two validated models, the University of California Los Angeles Integrated Staging System (UISS) 5, 6 and the Stage, SIze, Grade, and Necrosis score (SSIGN). 7 The UISS is based on TNM classification, Fuhrman grade and Eastern Cooperative Oncology Group performance status (ECOG PS) before nephrectomy. Using UISS, a highrisk population for recurrence can be described: T3 N0 or Nx, Fuhrman grade ≥2, ECOG ≥1 and T4 and/or nodal involvement, for whom the risk rate of recurrence at 5 years is approximately 60%, arising in a median time of 9.5 months. [5] [6] [7] [8] [9] Using SSIGN, the estimated metastasisfree survival at 5 years is only 31.2%. 7, 10, 11 All previous prospective trials in adjuvant setting for RCC were reported negative. 4 So, effective adjuvant therapy for RCC is an unmet medical need for patients, especially for patients having a high risk of recurrence.
Three pivotal phase III studies have been recently published in the adjuvant setting for RCC: ASSURE, S-TRAC and PROTECT. [12] [13] [14] One has been positive: S-TRAC, one has been negative but including positive outcomes: PROTECT and one being negative: ASSURE.
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This review provides a view on differences between these three trials, which may be taken into account to hypothesize on reasons for different final results.
ARGUMENTS TO EVALUATE ANTI-ANGIOGENIC THERAPY IN ADJUVANT RCC PATIENTS
There is no question on the involvement of neoangiogenesis in metastatic setting of RCC, with different drugs able to improve the outcome for these patients. 15, 16 Some arguments may justify considering vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR TKI) to inhibit development of micro-metastases in adjuvant setting.
VEGFR TKI have demonstrated ability to delay framework of neoangiogenesis including impairment of cancer stem cell endothelial differentiation. 17 VEGFR2 has been found on renal tumor cell surfaces. 18 VEGFR TKI have been reported to potentially be cytotoxic on tumor cell lines. 19, 20 In addition to impact on angiogenesis and a potential cytotoxicity, VEGFR TKI have been reported to impact on immune tumoral surrounding by inhibiting functions of Treg and myeloid-derived tumor cells. 21 At this point it is unclear so far about the action on adjuvant setting by a direct impact or an indirect impact influencing involution, apoptosis and/or dormancy.
Nevertheless, the hypothesis generated when we, investigators of S-TRAC, designed the trial was to consider if VEGFR TKI is relevant in adjuvant setting was that patients with high-risk tumors for recurrence have more chance that angiogenesis is implicated and early, and/or sunitinib to be active than for lower risk patients. Clearly, there is an increase of risk over these three studies. In addition, the number of events varies in consequence impacting the followup, the duration of the study and the chance to be positive in a certain period of time, if any.
The starting dose of sunitinib in S-TRAC was 50 mg/day for 4 weeks every 6 weeks with a dose decrease allowed to 37.5 mg/day. No alternative schedule as 2 weeks on and 1 week off was allowed. In ASSURE, sunitinib was started initially at the same standard dosage but after inclusion of 30% of recruitment, the initial dose was decreased to 37.5 mg/day. The dose decrease was allowed to 25 mg. A similar attitude was proposed to sorafenib, the third arm of ASSURE. In PROTECT, the initial dose of pazopanib was standard at 800 mg/day continuously and was decreased after inclusion of 26% to pazopanib at 600 mg/day.
Treatment duration for these studies was 1 year.
STUDY DESIGN
All three studies included a specific population of risk (see above) and randomization was on a 1:1 ratio when two arms (S-TRAC: sunitinib vs placebo; PROTECT: pazopanib vs placebo) and a 1:1:1 ratio when three arms (ASSURE: sunitinib vs sorafenib vs placebo). Stratification for risk or specific population was done in each trial. Disease-free survival (DFS) was the primary endpoint for all studies (Figure 2 ).
RESULTS
S-TRAC showed a significant increase in DFS on independent review reaching the primary endpoint whereas ASSURE and PROTECT did not.
In the S-TRAC trial, 13 in the sunitinib arm and 74 patients in the placebo arm had died. 22 The median OS was not reached in sunitinib or in placebo arm after a median follow-up duration of 6.6 and 6.7 years, respectively in the placebo arm (HR = 0.92; 95% CI, 0.66-1.28; P = 0.6).
The ASSURE trial 12 subgroup analysis including high-risk patients reported a difference. 23 OS was not different among patients whatever treatment or placebo was received. 12, 23 The PROTECT trial included 1538 patients with RCC at moderate or high risk of recurrence. 14 Considering the primary endpoint on DFS for patients (n = 1135) under pazopanib at 600 mg/day or placebo, no difference was reported (HR = 0.862; 95% CI, 0.699-1.063; P = 0.165].
Nevertheless, when DFS is analyzed, as a secondary endpoint, for patient receiving pazopanib at 800 mg/day (n = 403), a reduction of 31% in relapse risk versus placebo is reported (HR = 0.693; 95% CI, 0.510-0.943). 14 For these patients, the difference in the rate of DFS at 3 years was in favor of pazopanib compared to placebo at 66% versus 56% (+10%). Overall, a 20% reduction in relapse risk was observed in the entire population with pazopanib (600 or 800 mg/day) versus placebo (HR = 0.802; 95% CI, 0.67-0.95).
As probably dose matters in the way it may influence dose exposure, which is probably the more accurate parameter impacting dose-effect, at least demonstrated in the metastatic setting, 24 the median cumulative dose of sunitinib in S-TRAC was 9638 mg (range 100-13 800) and 6800 mg (range 2600-9900) in ASSURE.
Concerning the safety of adjuvant treatment, the side effects profile did not differ from the metastatic setting reports, except for more frequent and severe hand-foot syndrome. [12] [13] [14] In S-TRAC, handfoot syndrome (16%), neutropenia (8.5%), and hypertension (7.8%) occurred as ≥grade 3 or 4 in > 5% of patients. 13 In ASSURE, hypertension (17% and 16%), fatigue (18% and 7%), hand-foot syndrome (15% and 33%) and rash/desquamation (2% and 15%) were reported in more than 10% of the patients as grade 3 or 4 for sunitinib and sorafenib, respectively. 12 Finally, in PROTECT more than 10% of patients reported grade 3/4 hypertension (25%) and increased alanine aminotransferase (16%) under pazopanib. 14 Despite modification of the starting dose, there was no significant modification of the safety profile or a reduction in cessation for toxicity. 25 The analysis of site of progression in S-TRAC did not show any difference between the experimental arm and the placebo, suggesting no impairment of subsequent evolution by giving sunitinib in adjuvant setting even when the patient relapses afterwards. 22 Finally, the patient perspective was considered by asking 22 patient representatives from the IKCC their position if they were offered adjuvant treatment: "After surgery for kidney cancer, if your doctor told that you are at high risk of recurrence (spread), would you consider taking sunitinib (Sutent) for 1 year in the hope you could delay the onset of recurrence even if your OS was not improved?' When a also asked, "What degree of DFS advantage would be needed to justify taking sunitinib for 1 year knowing that there is no improvement in OS?," close to 70% of the patients said they would agree to take sunitinib in adjuvant if DFS ≥5 years. 26 
CONCLUSION
At this time, based on S-TRAC results, sunitinib has been approved by FDA in adjuvant setting in RCC for patients at high-risk of recurrence after nephrectomy. If the drug is approved by the authorities, sunitinib in adjuvant should be considered as an option to be presented to the patient. Information should be given on what is known on DFS gain, OS data and safety profile in reaching a decision. Keeping on the standard starting dose at 50 mg, ensuring good drug management and decreasing only to 37.5 mg, if necessary, are important considerations for optimal sunitinib use.
